NASDAQ: CNXUConexeu Sciences Inc Stock
$10.20+0.29 (+2.93%)
Updated Jul 10, 2026
CNXU Price
$10.20
Fair Value Price
N/A
Market Cap
$272.93M
52 Week Low
$8.14
52 Week High
$18.79
P/E
N/A
P/B
37.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
N/A
Beta
-0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNXU Overview
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNXU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CNXU news, forecast changes, insider trades & much more!
CNXU News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNXU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNXU is poor value based on its book value relative to its share price (37.93x), compared to the US Biotechnology industry average (5.52x)
P/B vs Industry Valuation
CNXU's short-term assets ($7.91M) exceed its short-term liabilities ($1.00M)
Short-term Liabilities Financials
CNXU's short-term assets ($7.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CNXU due diligence checks available for Premium users.
Valuation
CNXU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
37.93x
Industry
5.52x
CNXU is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNXU's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
Assets to liabilities
Assets
$8.2M
Liabilities
$1.0M
Debt to equity
0.14
CNXU's short-term assets ($7.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNXU's short-term assets ($7.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNXU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
-$30.1k
Financing
$2.4M
CNXU vs Biotech Stocks
Conexeu Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.